Tilray Brands Board Overhaul Falls Short Despite 77% Support; CEO Targets $30 Million in Savings

Tilray Brands logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Board declassification failed despite receiving about 77% of votes cast, because it did not reach the required two-thirds of all outstanding shares. Shareholders re-elected three directors and approved the auditor.
  • Tilray is targeting about $30 million in annualized savings from U.S. brewing and Canadian cannabis restructuring, with full savings expected in fiscal 2028. It forecasts fiscal 2027 adjusted EBITDA of $70 million to $75 million.
  • Fiscal 2026 revenue and adjusted EBITDA each rose 11%, to $915 million and $61 million, respectively. CEO Irwin Simon acknowledged shareholder concerns about the stock price and dilution, saying the company aims to rely less on share offerings by generating cash, cutting costs and reducing debt.
  • Interested in Tilray Brands? Here are five stocks we like better.

Tilray Brands NASDAQ: TLRY shareholders re-elected three directors and ratified the company’s auditor at its annual meeting, but a proposal to declassify the board fell short of the required support despite receiving a majority of votes cast.

Chairman and CEO Irwin Simon also outlined plans to cut costs across Tilray’s U.S. beverage and Canadian cannabis operations, reiterated the company’s fiscal 2027 earnings outlook and addressed shareholder concerns about its declining stock price and equity dilution.

Governance proposal falls short

Mitch Gendel, Tilray’s global general counsel and corporate secretary, said preliminary results showed that David Clanachan, Renah Persofsky and Simon were each re-elected as Class II directors for terms expiring in 2029. Clanachan received more than 67% of votes cast, Persofsky more than 56% and Simon more than 60%.

Shareholders also ratified PricewaterhouseCoopers LLP as Tilray’s independent registered public accounting firm for the fiscal year ending May 31, 2027, with approximately 87% of votes cast in favor.

A governance proposal would have declassified the board and eliminated a charter provision permitting shareholders to remove directors only for cause. Although approximately 77% of votes cast supported the measure, Gendel said it failed to secure the required support from two-thirds of outstanding shares.

More than 57.9 million shares, or 39.6% of outstanding shares entitled to vote, were represented at the meeting, constituting a quorum, Gendel said.

Cost cuts and earnings outlook

Simon said Tilray recently raised the lower end of its fiscal 2027 adjusted earnings before interest, taxes, depreciation and amortization guidance. The company now expects adjusted EBITDA of $70 million to $75 million, or approximately 15% to 23% above fiscal 2026.

In the United States, Tilray has reduced its brewing network from 10 facilities to six and is consolidating its distributor network. Those initiatives target approximately $20 million in annualized savings by the end of fiscal 2028, Simon said.

In Canada, Tilray is closing its Foss cannabis facility and consolidating cultivation at Masson and pre-roll production at Cayuga. The company is targeting approximately $10 million in annualized savings from those changes, with the full run rate beginning in fiscal 2028.

Simon said Tilray is working to recertify Masson for international exports and sees potential to increase annual cultivation capacity there from approximately 32.5 metric tons to 50 metric tons.

Revenue growth and shareholder concerns

Tilray reported fiscal 2026 net revenue of $915 million, up 11% year over year, and adjusted EBITDA of $61 million, also up 11%, Simon said. He put annualized pro forma revenue at approximately $1.2 billion, reflecting full-year contributions from acquired businesses, including BrewDog.

The company ended fiscal 2026 with approximately $235 million in cash, restricted cash and marketable securities, and improved operating cash flow by about $25 million year over year, Simon said. He added that Tilray reduced debt during the year and lowered its convertible note balance by another $40 million after fiscal year-end.

Simon acknowledged frustration over the share price and said Tilray uses at-the-market offerings to finance selected acquisitions and investments. The company is working toward needing fewer stock offerings by generating cash, reducing debt and lowering costs, he said.

Beverage and international cannabis expansion

Simon said Tilray completed its BrewDog acquisition through four transactions for about $54 million and has returned the brand to profitability under its ownership. Since the relaunch, Punk IPA sales across BrewDog’s top six off-trade retailers rose 187% year over year, he said.

Tilray also plans to launch an exclusive U.S. partnership with Carlsberg on Jan. 1, 2027, targeting at least 1 million cases in the first year. The partnership will bring Carlsberg Elephant and 1664 Blanc into Tilray’s U.S. beverage platform, Simon said.

In cannabis, Simon said international revenue grew 34% in fiscal 2026. He cited expanded production capacity in Portugal and the acquisition of Lyphe as part of Tilray’s international medical cannabis strategy. The company’s pharmaceutical distribution revenue rose 21% to $327 million, he said.

About Tilray Brands (NASDAQ:TLRY)

Tilray Brands is a global cannabis and consumer packaged goods company. Its cannabis business produces and sells medical and adult-use products, including dried flower, oils, extracts and edibles, under brands such as Good Supply, Solei, Redecan and Broken Coast. The company serves customers in Canada, the United States and international markets. Its activities include medical cannabis distribution in countries where permitted, as well as cannabis and hemp-related products in North America, subject to local regulations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tilray Brands Right Now?

Before you consider Tilray Brands, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray Brands wasn't on the list.

While Tilray Brands currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines